> > > 【肺癌】臨床研究

【肺癌】臨床研究

臨床腫瘍グループ-臨床研究1

臨床研究

  • IL6発現とEGFR-TKIの効果についての研究
  • EGFR-TKI期間におけるPS低下因子の研究
  • プラチナ再チャレンジの臨床効果についての研究
  • シスプラチン ショートハイドレーションの有効性解析
  • BSAとEGFR-TKIの治療効果についての研究
  • OLCSG/JCOG
  • 岡山肺癌治療研究会(OLCSG)の事務局として,多くの臨床試験を施行してします。 また,日本臨床腫瘍グループ(JCOG)の一員として臨床試験に協力しています

OLCSG

臨床研究により診療ガイドライン等へ貢献

現在進行中の主な臨床試験

  • OLCSG 0102: Phase II study of topotecan and cisplatin for elderly small-cell lung cancer
  • OLCSG 0403: Randomized comparative study of cisplatin, docetaxel, and irinotecan versus cisplatin and docetaxel in patients with stage IIIB or stage IV non-small cell lung cancer
  • OLCSG 0704: Phase II study of cisplatin, docetaxel, and irinotecan, followed by gefitinib, gemcitabine and vinorelbine for patients with non-small-cell lung cancer harboring active EGFR gene mutations
  • OLCSG0902: 化学療法既治療の再発肺非小細胞癌に対するイリノテカン、アムルビシン、ベバシズマブ併用療法の第II相試験
  • OLCSG1202: 野生型EGFR遺伝子を有する高齢者未治療進行非小細胞肺癌に対するカルボプラチンとS-1併用療法の第Ⅱ相試験
  • OLCSG1301: ALK遺伝子融合変異を有する全身状態不良非小細胞肺癌患者に対するクリゾチニブの有用性を検討する第II相試験
  • OLCSG1302: 肺小結節影の経過を調査する前向きコホート研究
  • OLCSG1303: Phase I/II Trial of weekly nab-Paclitaxel as second line treatment in patients with Advanced Non-small-cell lung cancer
  • OLCSG1401: 非小細胞肺癌化学放射線療法における放射線食道炎に対するアルギン酸ナトリウムの有用性を検討する無作為化比較試験

臨床腫瘍グループ-臨床研究2

 論文・業績  

Publication from OLCSG

Small Cell Lung Cancer (clinical trial)

  • Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer. Cancer 1993
  • Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response: a long-term follow-up result. Lung Cancer 1993
  • Long-term results of combination chemotherapy with or without irradiation in small cell lung cancer: a 5- to 11-year follow-up. Intern Med 1993
  • Mortality and morbidity in two-year disease-free survivors of small cell lung cancer after treatment with combination chemotherapy with or without irradiation. Acta Medica Okayama 1993
  • A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up. Cancer 1998
  • Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer. Jpn J Cancer Chemother 2002
  • Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer. Lung Cancer 2003
  • Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study. Anticancer Res 2003
  • A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer. Cancer Chemother Parmacol 2007

Non-Small Cell Lung Cancer (clinical trial)

  • Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer. Acta Med Okayama 1991
  • A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer 2000
  • Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group Br J Cancer 2001
  • A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer 2002
  • Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 2003
  • Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemother Pharmacol 2004
  • A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemother Pharmacol 2007
  • Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer.Anticancer Res 2006
  • Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial. J Thoracic Oncol 2007
  • A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503. J Thorac Oncol. 2010
  • Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010
  • A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.  J Thorac Oncol. 2010
  • A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. Lung Cancer. 2011
  • Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402. Acta Oncol. 2012

Combination phase I trial

  • Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. Br J Cancer 1999
  • Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer. Lung Cancer 2004
  • A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer 2004
  • Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res 2005
  • A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer. Cancer Chemother Pharmacol 2006
  • A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.. Lung Cancer 2006
  • A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. Lung Cancer 2009
  • A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer. Lung Cancer. 2011

 Meta-analysis

  • A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992
  • Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999

Others

  • Prognostic factors of small-cell lung cancer in Okayama Lung Cancer Study Group Trials. Acta Med Okayama 1998
  • Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol 2005
  • Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005
  • Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Ann Oncol 2005
  • Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study. Lung Cancer 2005
  • Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. Br J Cancer 2006
  • Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol 2008
  • Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. J Cancer Res Clin Oncol 2009
  • Desire for information and involvement in treatment decisions: lung cancer patients’ preferences and their physicians’ perceptions: results from Okayama Lung Cancer Study Group Trial 0705. J Thorac Oncol. 2010
  • Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Lung Cancer. 2010
  • Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol. 2010
  • Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007. J Thorac Oncol. 2011
  • Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer. 2012
  • Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol. 2014
  • Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol. 2013

 

OLCSG参加施設

Participating institutions to OLCSG

  • Okayama University Hospital, Okayama
  • Shikoku Cancer Center Hospital, Matsuyama
  • Sumitomo Besshi Hospital, Niihama
  • Chugoku Central Hospital, Fukuyama
  • Yamaguchi Ube Medical Center, Ube
  • Okayama Red Cross General Hospital, Okayama
  • Ehime Prefectural Central Hospital, Matsuyama
  • Okayama Rosai Hospital, Okayama
  • Kure Kyosai Hospital, Kure
  • Okayama Medical Center, Okayama
  • Minami-Okayama Medical Center, Hayashima
  • Fukuyama Medical Center, Fukuyama
  • Tsuyama Central Hospital, Tsuyama
  • Kawasaki Hospital, Okayama
  • Kagawa Rosai Hospital, Marugame
  • Yashima General Hospital, Takamatsu
  • Okayama Saiseikai General Hospital, Okayama
  • Kurashiki Central Hospital, Kurashiki
  • Iwakuni Medical Center, Iwakuni